drugset / Trial / NCT06122311

Drug Nephrotoxicity Amelioration by N-acetylcysteine

NCT06122311

Completed 100 enrolled Helwan University
RandomizedParallel-groupOpen-labelPrevention

Summary

When treating individuals with febrile neutropenia, amphotericin B (AmB-d) is one of the most effective treatments against often fatal systemic fungal infections.Nephrotoxicity from amphotericin B can develop with an incidence of up to 80.This emphasizes the value of nephroprotectant agent use.Because of N-acetylcysteine's antioxidant, antiapoptotic, vasodilator properties and its therapeutic effects on contrast nephropathy. Acetylcysteine's impact on amphotericin B-induced nephrotoxicity in cancer patients is assessed.

Timeline

Start
2023-08-25
Primary completion
2024-06-10
Completion
2024-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 600 mg Oral

Indications

No indication recorded.